ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly Ups Commitment To Fight Tuberculosis

March 26, 2007 | APPEARED IN VOLUME 85, ISSUE 13

Eli Lilly & Co. is investing another $50 million in the Lilly MDR-TB Partnership, a consortium of 14 public and private organizations aligned to battle multi-drug-resistant tuberculosis. The cash influx brings Lilly's total investment in the project during the past four years to $120 million. Lilly also has provided several generic drugmakers with manufacturing and formulation technology needed to produce capreomycin and cycloserine, two Lilly antibiotics used to treat MDR-TB. In conjunction with Lilly's donation, the firms participating in the alliance will work to ramp up supplies of the antibiotics.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment